TSRO TESARO Inc.

34.96
+8.37  (+31%)
Previous Close 26.59
Open 26.46
Price To Book -14.69
Market Cap 1924441582
Shares 55,046,956
Volume 7,631,782
Short Ratio
Av. Daily Volume 1,707,149

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial to be initiated 1H 2018.
TSR-042
First-line ovarian cancer
Phase 1/2 data due 2H 2018.
Niraparib - AVANOVA
Ovarian cancer
Phase 1/2 trial ongoing. Data at ASCO 2018 noted ORR 25%.
Niraparib and Keytruda (TOPACIO)
Triple-negative Breast Cancer or Ovarian Cancer
Phase 3 data due late-2019.
Niraparib - PRIMA
First-line ovarian cancer
CRL January 11 2017. FDA Approval announced October 25, 2017 following resubmission.
Rolapitant - intravenous (IV)
Prevention of chemotherapy induced nausea and vomiting, or CINV in HEC patients
Phase 3 trial no longer be expected to serve as a registration trial - noted March 27, 2017.
Niraparib - BRAVO
Cancer - breast
PDUFA date under priority review was June 30, 2017. Approved March 27, 2017.
Niraparib - NOVA (Niraparib Ovarian)
Cancer - ovarian
Phase 2 top-line data released April 24, 2018. Primary endpoint met. sNDA to be potentially filed 2H 2018.
Niraparib - (QUADRA trial)
Cancer - ovarian
Approved September 2, 2015.
Rolapitant
Prevention of chemotherapy induced nausea and vomiting, or CINV in HEC patients
Phase 1 preliminary data at ESMO October 2018 noted ORR 52%. BLA filing 2019.
TSR-042 - GARNET
Solid tumors
Phase 2 initial data due 1H 2019.
Niraparib - JASPER
Non-small cell lung cancer (NSCLC)
Phase 1 data at SITC Novemeber 2018 - 15% ORR for high dose , 9% ORR for lower dose.
TSR-022 + TSR-042 AMBER
Solid tumors
Phase 2 presentation at ESMO October 2018.
Niraparib + bevacizumab OVARIO
Ovarian cancer
Phase 1 trial ongoing.
TSR-033 - CITRINO
Solid tumors

Latest News

  1. IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Tesaro, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
  2. SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Tesaro, Inc. of Class Action Lawsuit and Upcoming Deadline – TSRO
  3. CLASS ACTION UPDATE for COST, TSRO and MGI: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
  4. SHAREHOLDER ALERT- Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Tesaro, Inc. (TSRO) and Lead Plaintiff Deadline: January 9, 2019
  5. See what the IHS Markit Score report has to say about TESARO Inc.
  6. SHAREHOLDER ALERT: APOG COCP COST TRVN HON DY ALGN AQUA SONS TSRO: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
  7. Tesaro, Clovis Rally on FDA Priority Review for Lynparza sNDA
  8. Election Night Cannabis Approvals Could Benefit These Companies
  9. AstraZeneca's Lynparza Gets Priority Review in 1st Line Use
  10. CLASS ACTION UPDATE for IGCC, ALGN, AQUA and TSRO: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
  11. Do Options Traders Know Something About TESARO (TSRO) Stock We Don't?
  12. Pomerantz Law Firm Announces the Filing of a Class Action against Tesaro, Inc. and Certain Officers – TSRO
  13. Here's Why AnaptysBio, Inc. Slipped on Friday
  14. TESARO Announces Immuno-Oncology Data Presentations at SITC 2018 Annual Meeting
  15. AnaptysBio Inc. Sets Up More Shots on Goal in the Third Quarter
  16. Edited Transcript of TSRO earnings conference call or presentation 1-Nov-18 8:15pm GMT
  17. TESARO (TSRO) Q3 Earnings Beat, Revenues Miss, Shares Up